tetano
Editor, Senior Moderator
Future Virol
. 2021 Nov;10.2217/fvl-2021-0311.
doi: 10.2217/fvl-2021-0311. Epub 2021 Dec 15.
Performance of six SARS-CoV-2 RNA detection systems in symptomatic and asymptomatic pediatric and maternal patients
Cameron A Brown[SUP] 1 2 [/SUP], Megan H Amerson-Brown[SUP] 1 2 [/SUP], Aliza Rahman[SUP] 1 [/SUP], Charity R Webb[SUP] 1 [/SUP], Ila R Singh[SUP] 1 2 [/SUP], James J Dunn[SUP] 1 2 [/SUP]
Affiliations
Abstract
Aim: This study evaluated the real-world performance of six test systems for detection of SARS-CoV-2 in 138 pediatric and 110 adult maternal patients. Materials & methods: Nasopharyngeal swabs were tested directly using the Aptima™ SARS-CoV-2 (Aptima) and Simplexa™ COVID-19 Direct (Simplexa), and with Altona RealStar[SUP]®[/SUP] RT-PCR and CDC RT-PCR with nucleic acid extracted on the Roche[SUP]®[/SUP] MagNA Pure 96 (Altona-MP96) or bioMérieux EMAG[SUP]®[/SUP] (Altona-EMAG). Results/Conclusion: Overall percent-positive and percent-negative agreements among the six test systems were, respectively: Aptima: 94.8 and 100%; Altona-MP96: 96.5 and 99.3%; CDC-MP96: 100 and 99.3%; Altona-EMAG: 86.1 and 100%; CDC-EMAG: 98.2 and 100%; Simplexa: 87 and 99.2%. The six test systems showed agreement ranging from 92.7 (κ = 0.85) to 98.8% (κ = 0.98).
Keywords: RNA extraction; RT-PCR; SARS coronavirus; respiratory infection; surveillance.
. 2021 Nov;10.2217/fvl-2021-0311.
doi: 10.2217/fvl-2021-0311. Epub 2021 Dec 15.
Performance of six SARS-CoV-2 RNA detection systems in symptomatic and asymptomatic pediatric and maternal patients
Cameron A Brown[SUP] 1 2 [/SUP], Megan H Amerson-Brown[SUP] 1 2 [/SUP], Aliza Rahman[SUP] 1 [/SUP], Charity R Webb[SUP] 1 [/SUP], Ila R Singh[SUP] 1 2 [/SUP], James J Dunn[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35027939
- PMCID: PMC8734120
- DOI: 10.2217/fvl-2021-0311
Abstract
Aim: This study evaluated the real-world performance of six test systems for detection of SARS-CoV-2 in 138 pediatric and 110 adult maternal patients. Materials & methods: Nasopharyngeal swabs were tested directly using the Aptima™ SARS-CoV-2 (Aptima) and Simplexa™ COVID-19 Direct (Simplexa), and with Altona RealStar[SUP]®[/SUP] RT-PCR and CDC RT-PCR with nucleic acid extracted on the Roche[SUP]®[/SUP] MagNA Pure 96 (Altona-MP96) or bioMérieux EMAG[SUP]®[/SUP] (Altona-EMAG). Results/Conclusion: Overall percent-positive and percent-negative agreements among the six test systems were, respectively: Aptima: 94.8 and 100%; Altona-MP96: 96.5 and 99.3%; CDC-MP96: 100 and 99.3%; Altona-EMAG: 86.1 and 100%; CDC-EMAG: 98.2 and 100%; Simplexa: 87 and 99.2%. The six test systems showed agreement ranging from 92.7 (κ = 0.85) to 98.8% (κ = 0.98).
Keywords: RNA extraction; RT-PCR; SARS coronavirus; respiratory infection; surveillance.